Omada Health, Inc. AI Stock Analysis
Want to see OMDA full AI Analyst Report?
Omada Health, Inc. (OMDA) AI Stock Analysis
Omada Health, Inc.
(NASDAQ:OMDA)
The score is driven primarily by improving fundamentals (growth, margin expansion, and the 2025 move to positive operating/free cash flow) and a supportive earnings update with raised guidance. These positives are tempered by weak technical positioning (below key moving averages with negative MACD) and a stretched valuation (very high P/E with no dividend support).
Omada Health, Inc. (OMDA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $945.45M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.27M
- Price to Earnings (P/E)
- 64.1
- Beta (1Y)
- 2.41
- Revenue Growth
- 43.34%
- EPS Growth
- ―
- Country
- US
- Employees
- 946
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Healthcare Information Services
Omada Health, Inc. Business Overview & Revenue Model
Company Description
Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States. The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to ad...
How the Company Makes Money
Omada Health primarily makes money by selling access to its virtual chronic care programs to healthcare payers and purchasers, most commonly health plans and self-insured employers (often accessed via benefits consultants and similar intermediaries)....
Omada Health, Inc. Earnings Call Summary
The call was strongly positive. Omada reported record revenue, gross margin, net income, adjusted EBITDA, member tenure, and cash generation, while raising full-year revenue and adjusted EBITDA guidance. Growth was supported by diabetes and hypertension programs, improved enrollment conversion, broader distribution, longer member engagement, and lower cost to serve. The main challenges were normal Q4 seasonal moderation, uncertainty around employer GLP-1 coverage and the timing of the extended selling season, rising healthcare costs, and expected near-term investment-related moderation in adjusted EBITDA.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Omada raised full year 2026 revenue guidance to $344 million to $346 million, up from $334 million to $340 million, and full year adjusted EBITDA guidance to $32 million to $34 million, up from $21 million to $27 million; at the midpoint, revenue represents approximately 33% growth compared with 2025, while adjusted EBITDA represents an improvement of approximately $27 million compared with 2025 or roughly 5.5x 2025 adjusted EBITDA. Q4 revenue is expected to be below Q3, with new enrollments expected to moderate sequentially and revenue coming primarily from continued engagement among existing members; Q4 adjusted EBITDA is expected to moderate from Q3 as the company adds R&D headcount and ramps care team staffing for the 2027 benefit launch. For 2027, management cited a 20%+-plus growth target, expects the additional estimated 1.5 million covered lives from HCSC to launch on January 1 and phase throughout the entire year, and continues to target 80% longer-term gross margin.
Omada Health, Inc. Financial Statement Overview
Summary
Financial statements show a strong improvement trajectory: rapid revenue growth, expanding gross margin, sharply narrowing losses, and a shift to positive operating and free cash flow in 2025. The balance sheet is a key positive with no reported debt and a larger equity base, reducing solvency risk. The main constraint on the score is that profitability is not yet fully established on a sustained basis and cash-flow consistency is still being proven after prior-year burn.
Income Statement
72PositiveBalance Sheet
78PositiveCash Flow
70Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 333.04M | 260.21M | 169.80M | 122.78M | 89.19M |
| Gross Profit | 235.42M | 170.94M | 102.88M | 69.97M | 42.79M |
| EBITDA | 16.88M | -4.75M | -37.83M | -58.36M | -63.99M |
| Net Income | 5.16M | -12.78M | -47.14M | -67.51M | -72.52M |
Balance Sheet | |||||
| Total Assets | 348.54M | 305.41M | 150.89M | 175.08M | 221.80M |
| Cash, Cash Equivalents and Short-Term Investments | 243.15M | 222.04M | 76.39M | 115.64M | 168.12M |
| Total Debt | 0 | 0 | 30.19M | 30.58M | 30.81M |
| Total Liabilities | 75.38M | 75.73M | 86.26M | 76.16M | 66.19M |
| Stockholders Equity | 273.16M | 229.68M | 64.63M | 98.92M | 155.60M |
Cash Flow | |||||
| Free Cash Flow | 23.68M | 16.93M | -38.04M | -52.66M | -71.70M |
| Operating Cash Flow | 28.69M | 18.25M | -34.18M | -49.74M | -68.98M |
| Investing Cash Flow | -6.20M | -5.83M | -3.86M | -2.92M | -2.72M |
| Financing Cash Flow | 22.03M | 133.22M | -1.21M | 179.00K | 16.32M |
Omada Health, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OMDA, the sentiment is Negative. The current price of 15.24 is below the 20-day moving average (MA) of 18.12, below the 50-day MA of 19.63, and below the 200-day MA of 17.72, indicating a bearish trend. The MACD of -1.16 indicates Positive momentum. The RSI at 32.67 is Neutral, neither overbought nor oversold. The STOCH value of 12.64 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OMDA.
Omada Health, Inc. Risk Analysis
Omada Health, Inc. disclosed 82 risk factors in its most recent earnings report. Omada Health, Inc. reported the most risks in the "Ability to Sell" category.
Latest Risks Added
3 New RisksOmada Health, Inc. Peers Comparison
Overall Rating
HNGE81Outperform- OMDA68Neutral
GDRX65Neutral
PRVA59Neutral
AMWL57Neutral
TDOC56Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HNGE | 81Outperform | $9.60B | 58.52 | 50.47% | ― | 49.86% | ― |
| OMDA | 68Neutral | $934.29M | 64.06 | 5.67% | ― | 43.34% | ― |
| GDRX | 65Neutral | $1.21B | 69.39 | 2.61% | ― | -1.83% | -48.77% |
| PRVA | 59Neutral | $3.11B | 86.16 | 4.50% | ― | 19.19% | 84.88% |
| AMWL | 57Neutral | $206.99M | -3.58 | -25.49% | ― | -20.30% | 52.30% |
| TDOC | 56Neutral | $1.63B | -10.39 | -11.63% | ― | -2.38% | 32.73% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| OMDA | Omada Health, Inc. | 15.24 | -5.53 | -26.62% | |
| TDOC | Teladoc Inc. | 8.94 | 1.87 | 26.45% | |
| AMWL | American Well Corporation | 12.31 | 8.32 | 208.52% | |
| GDRX | Goodrx Holdings, Inc. | 3.65 | 0.58 | 18.89% | |
| PRVA | Privia Health Group, Inc. | 24.04 | 0.29 | 1.22% | |
| HNGE | Hinge Health, Inc. Class A | 121.72 | 79.97 | 191.54% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026